Because of the drug resistance and toxicity, the use of doxorubicin is limit in the clinic. This protocol provides a degradable carrier for keeping the release of this therapeutic agent. The advantage of this method is that the synthesized carrier
Connectez-vous ou commencez votre essai gratuit pour accéder à ce contenu.
In this protocol, doxorubicin-loaded AS1411-g-PEI-g-PEG modified gold nanoparticles are synthesized via three-step amide reactions. Then, doxorubicin is loaded and delivered to target cancer cells for cancer therapy.